This study aimed to compare the efficacy and safety of arthroscopy with physiotherapy or joint lavage in patients with femoroacetabular impingement (FAI). A meta-analysis using PubMed, Embase, Scopus, and the Cochrane Collaboration Library databases was performed in September 2022. We included studies focusing on patients with FAI who underwent arthroscopic surgery versus those who underwent physiotherapy or arthroscopic lavage. The outcomes were functional scores (iHOT-33 and HOS ADL) and adverse events. Randomized clinical trials were included in the study. The risk of bias in each study was assessed according to Cochrane guidelines for clinical trials. The data were combined using Review Manager version 5.4. (PROSPERO CRD42022375273). Six RCTs were included, from a pool of 839 patients (407 females). There were no significant differences between groups at 6 months regarding iHOT-33 (MD 4.68, 95% CI -0.07 to 9.44) and HOS ADL (MD 5.09, 95% CI -0.07 to 10.24). The iHOT-33 and HOS ADL scales showed significant differences at 12 months in favor of the arthroscopy group (MD 10.65, 95% CI 6.54 to 14.76) and (MD 8.06, 95% CI 1.05 to 15.07). MCID was not achieved through arthroscopy in functional variables. The rate of numbness was significantly higher in the arthroscopy group. Although the arthroscopy group demonstrated statistical superiority, the clinical significance based on the MCID remains controversial, and arthroscopy did not demonstrate clinical superiority.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882802 | PMC |
http://dx.doi.org/10.1038/s41598-025-91788-1 | DOI Listing |
J World Fed Orthod
March 2025
Dental Research Center, Orthodontics Department, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:
Objectives: This randomized two-arm parallel trial aimed to compare the effectiveness of standard anterior bracket positioning with the smile arc protection (SAP) method in terms of occlusal and smile morphometric indices, and perceived post-treatment smile aesthetics.
Methods: Patients needing nonextraction orthodontic treatment were randomly assigned to either the SAP or standard bracket placement group. Inclusion criteria were ages 11 to 25 years, nonextraction treatment, and good oral hygiene, all treated using the Roth 0.
JACC Cardiovasc Interv
March 2025
Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, Department of Medicine, Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York, USA.
Background: Severe calcification is the morphology most strongly associated with stent underexpansion.
Objectives: The aim of this study was to revise an optical coherence tomography (OCT)-derived calcium score to predict stent underexpansion in severely calcified lesions (angle >270°) using a point-based system.
Methods: A retrospective observational study was conducted in which 250 de novo lesions undergoing OCT-guided stenting, with angiographically visible calcium and optical coherence tomographic maximum superficial calcium angle >270°, not subjected to atherectomy or specialty balloon treatment before stent implantation, were randomly divided into derivation (n = 167) and validation (n = 83) cohorts.
Best Pract Res Clin Haematol
December 2024
330 Brookline Ave, Boston, MA, 02215, USA. Electronic address:
The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL. In this review, we focus primarily on Diffuse Large B-cell Lymphoma (DLBCL), highlighting the evolution, comparison, tolerability, ongoing challenges, and future potential of bispecific antibodies that are currently approved or in clinical trials for B-NHL.
View Article and Find Full Text PDFJ Am Coll Cardiol
March 2025
National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a selective, oral transthyretin stabilizer recently approved by the U.S.
View Article and Find Full Text PDFJ Med Chem
March 2025
EaStCHEM School of Chemistry, University of Edinburgh, David Brewster Road, Edinburgh, Scotland EH9 3FJ, U.K.
Cyclophilins have been implicated in the pathophysiology of metabolic dysfunction-associated steatohepatitis (MASH). Pharmacological inhibition of the cyclophilin B isoform has the potential to attenuate liver fibrosis in MASH, but current cyclophilin inhibitors in clinical trials lack isoform selectivity. We previously reported the novel tri-vector small-molecule inhibitor that exhibited improved subtype selectivity by simultaneously engaging three pockets on the surface of cyclophilins.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!